Avas EZ Tablets (Atorvastatin + Ezetimibe )

• Composition :
  Each tablet contains Atorvastatin 10 mg and + Ezetimibe 10mg.
• Indications :
  The combination is intended for the treatment of hypercholesterolemia.
• Pharmacodynamics :
  Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate which is an early rate-limiting step in cholesterol biosynthesis. Ezetimibe inhibits the absorption of cholesterol from the intestine, thus decreasing the delivery of intestinal cholesterol to the liver.
• Dosage and administration :
  One tablet once daily orally, with or without food.
• Contraindications :
  Active liver disease, hypersensitivity
• Precautions and warnings :
  It is contraindicated during hypersensitivity; active liver disease or unexplained persistent elevated liver function tests, during pregnancy and lactation. Skeletal muscle effects (e.g., myopathy and rhabdomyolysis).
• Use in pregnancy, lactation & pediatrics :
  Contraindicated in Lactation and Pregnancy. The long-term efficacy in pediatric population is not established.
• Drug interactions :
  Atorvastatin: Increases digoxin levels; increases anticoagulant effect of warfarin. Avoid the combination of HMG-CoA reductase inhibitors and fibrates. Cholestyramine decreases AUC of ezetimibe. Concomitant administration with, carbamazepine, rifampin not recommended because they may decrease ezetimibe/atorvastatin's effectiveness, anticoagulant should be administered with caution as risk of their side effects may be increased by ezetimibe/ atorvastatin.
• Adverse reactions :
  The most common adverse events are nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, flatulence, dyspepsia, myalgia, abdominal discomfort, asthenia
• Therapy Area :
  Lipid Lowering agents